SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Baruch D. Kuppermann, MD, discusses results of the phase 2 study of Allegro’s Luminate for the treatment of vitreomacular traction.
SEATTLE — Lisa Hark, PhD, director of glaucoma research at Wills Eye Hospital in Philadelphia, discusses data she is presenting at the Association for Research in Vision and Ophthalmology meeting on the incidence of glaucoma found in underserved populations in Philadelphia, particularly among African Americans.
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Rahul B. Khurana, MD, discusses a study looking at the as-needed arm of the HARBOR study, which showed the need for physicians to regularly monitor their patients with neovascular AMD.
SEATTLE — Patients with neovascular age-related macular degeneration who were treated with anti-VEGF therapy did not maintain visual gains at 5 years, according to the Comparison of Age-Related Macular Degeneration Treatment Trials results presented here. “Our primary goal of the CATT follow-up study was to assess the overall visual acuity and morphologic outcomes at 5 years of any anti-VEGF treatment,” Daniel F. Martin, MD, said at the Association for Research in Vision and Ophthalmology meeting.
SEATTLE — Community-based telemedicine can improve detection and management of patients with high-risk glaucoma and other diseases, according to a poster presented here.The Wills Eye Glaucoma Research Center initiated a 5-year community-based telemedicine intervention to improve the detection and management of high-risk glaucoma patients in Philadelphia, Lisa A. Hark, MD, and colleagues said at the Association for Research in Vision and Ophthalmology meeting.
Status: Active, not recruiting,
Condition Summary: Dry Eye Disease